RxDoctor Payments Data

Mohamed Shahed, MD

Internal Medicine · Fairview Park, OHNPI 1922075399

Payments from drug & device makers

$9,559in general payments, 2019–2025

Across 675 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$973
  • Lilly USA, LLC$480
  • Bayer$327
  • Amgen$325
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$9,548100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,559 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$143,032
Medicare patients
292
Services billed
7,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide400$495,204
MounjaroTirzepatide271$290,163
EliquisApixaban181$185,587
Radicava OrsEdaravone12$173,469
JardianceEmpagliflozin86$108,898
LinzessLinaclotide80$79,979
XareltoRivaroxaban61$56,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$53,504
FarxigaDapagliflozin Propanediol39$47,012
VraylarCariprazine Hcl31$43,316
Repatha SureclickEvolocumab33$35,861
RybelsusSemaglutide12$30,865
EntrestoSacubitril/Valsartan24$28,458
ProliaDenosumab13$22,629
WegovySemaglutide16$21,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$1,628$547,491428 claims
Lilly USA, LLCMounjaro, Trulicity$480$302,250282 claims
PfizerEliquis$186$185,587181 claims
AbbVieLinzess, Vraylar, Qulipta, Synthroid$2,790$143,131196 claims
Boehringer IngelheimJardiance$256$108,89886 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$973$64,18575 claims
GSKTrelegy Ellipta, Breo Ellipta$109$63,84365 claims
Johnson & JohnsonXarelto$13$56,90261 claims
NovartisEntresto$97$28,45824 claims
AmgenProlia$325$22,62913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$119$13,18527 claims
Astellas Pharma US IncMyrbetriq$48$9,41712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Fairview Park

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →